CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env
批准号:
7664143
负责人:
Shan Lu
金额:
$39.76万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-07 至 2014-03-31
关键词:
AntibodiesAntibody Binding SitesAntibody FormationAntigenic VariationAntigensBindingBinding SitesCharacteristicsClinical ResearchDNADataDrug FormulationsEpitopesHIVHIV vaccineHIV-1HumanImmune responseImmunizationIndividualLinkMasksMediatingModificationMolecular ConformationPatternPhasePhenotypePlayPolysaccharidesProteinsResistanceRoleScientistSerumStructureTestingVaccinesVariantViralVirusbaseenv Gene Productsglycosylationimmunogenicityneutralizing antibodypre-clinicalprogramssuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The main objectives of Project 2 are to identify primary HIV-1 envelope protein (Env) that have high ability in
eliciting antibodies against the CD4 binding site (CD4bs) and, if successful, to further select those Env
antigens that can also elicit broad neutralizing activities through the induction of anti-CD4bs antibodies.
Aim 1 To Identify variation in the antigenicity of the CD4bs for primary Envs of HIV-1.
CD4bs is a key target for eliciting broad neutralizing antibodies (NAbs) against HIV-1, as shown by
previous studies that had used mAb b12, and more recently, using sera from HIV infected individuals. Our
recent studies have shown that not every HIV primary Env antigen is equally effective in inducing NAb
responses. In Aim 1, we will test whether Envs from primary isolates of different backgrounds, phenotypes,
and clades may have varying antigenicity for both neutralizing and non-neutralizing CD4bs antibodies.
Aim 2 To understand the consequences of CD4bs antigenic variation on the neutralization
sensitivity of primary HIV-1 isolates.
It is well known that heavy glycosylation and epitope masking play a key role in resistance to
neutralization. Beyond these generalizations however, specific determinants of neutralization sensitivity or
resistance are difficult to identify due to the complexity of the Env and the often unknown interactions and
changes in conformation that occur as a result of trimerization of Env. In Aim 2, we intend to determine if
there is a link between CD4bs antigenicity and neutralization sensitivity.
Aim 3 To determine the immunogenicity of primary envelopes with varying levels of CD4bs
antigencity and to select Env antigens that can elicit anti-CD4bs mediated neutralizing activities.
The precise characteristics of a good HIV immunogen have yet to be identified. Previous studies have
made a number of attempts to increase the immunogenicity of the HIV Env with limited success. In Aim 3,
we will test whether the CD4bs antigenicity may be one, as of yet unidentified, determinant of a good
immunogen. Immunogenicity studies will be conducted with the DMA prime-protein boost approach to
identify those primary Env antigens that can elicit strong anti-CD4bs antibodies, possibly with broad
neutralizing activities as well.
RELEVANCE (Seeinstructions):
We plan to study the unique structure of HIV outside coat to find a common pattern on the coat that will allow
scientists to use them as part of the vaccine components to induce good protective immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati
-
批准号:8499206
-
项目类别:
-
资助金额:$234.3万
-
财政年份:2013
-
负责人:Shan Lu
-
依托单位:
Optimization of HIV vaccines for the induction of cross-reactive antibodies
-
批准号:7883581
-
项目类别:
-
资助金额:$236.62万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Optimization of HIV vaccines for the induction of cross-reactive antibodies
-
批准号:8303374
-
项目类别:
-
资助金额:$137.29万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Optimization of HIV vaccines for the induction of cross-reactive antibodies
-
批准号:8499205
-
项目类别:
-
资助金额:$294.72万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati
-
批准号:7701147
-
项目类别:
-
资助金额:$46.62万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Optimization of HIV vaccines for the induction of cross-reactive antibodies
-
批准号:7665598
-
项目类别:
-
资助金额:$231.33万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Administrative Core
-
批准号:7664150
-
项目类别:
-
资助金额:$17.22万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
-
批准号:8118542
-
项目类别:
-
资助金额:$197.58万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Administrative Core
-
批准号:7701150
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
-
批准号:8513885
-
项目类别:
-
资助金额:$202.66万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
-
批准号:7645923
-
项目类别:
-
资助金额:$185.76万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
-
批准号:8310009
-
项目类别:
-
资助金额:$200.73万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env
-
批准号:7907754
-
项目类别:
-
资助金额:$185.26万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Optimization of HIV vaccines for the induction of cross-reactive antibodies
-
批准号:8103325
-
项目类别:
-
资助金额:$605.04万
-
财政年份:2009
-
负责人:Shan Lu
-
依托单位:
Multi-gene Subunit Vaccine Platform Against Y. pestis
-
批准号:7684195
-
项目类别:
-
资助金额:$41.59万
-
财政年份:2008
-
负责人:Shan Lu
-
依托单位:
Multi-gene Subunit Vaccine Platform Against Y. pestis
-
批准号:7455420
-
项目类别:
-
资助金额:$40.26万
-
财政年份:2008
-
负责人:Shan Lu
-
依托单位:
Multi-gene Subunit Vaccine Platform Against Y. pestis
-
批准号:8129744
-
项目类别:
-
资助金额:$41.12万
-
财政年份:2008
-
负责人:Shan Lu
-
依托单位:
Multi-gene Subunit Vaccine Platform Against Y. pestis
-
批准号:7916646
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2008
-
负责人:Shan Lu
-
依托单位:
Polyvalent DNA Plus Protein HIV Vaccines
-
批准号:7167910
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2006
-
负责人:Shan Lu
-
依托单位:
Polyvalent DNA Plus Protein HIV Vaccines
-
批准号:7261244
-
项目类别:
-
资助金额:$40.57万
-
财政年份:2006
-
负责人:Shan Lu
-
依托单位:
海外基金